The role of drugs in the induction and/or exacerbation of psoriasis

International Journal of Dermatology

Volumn 49, Issue 12, 2010, Pages 1351-1361

  Basavaraj, Kabbur Hanumanthappa ^a   Ashok, Navya Mysore ^a   Rashmi, Ramesh ^a   Praveen, Thaggikuppe Krishnamurthy ^b  

^a JSS MEDICAL COLLEGE   (India)

^b JSS COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ALPRENOLOL; AMODIAQUINE; AMOXICILLIN; AMPICILLIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CETAMOLOL; CHLOROQUINE; CORTICOSTEROID; DOXYCYCLINE; HYDROXYCHLOROQUINE; INDOMETACIN; LITHIUM; LITHIUM CARBONATE; LITHIUM SALT; METOPROLOL; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXPRENOLOL; PENICILLIN G; PHENYLBUTAZONE; PINDOLOL; PRACTOLOL; PROPRANOLOL; PSYCHOTROPIC AGENT; RIFAMPICIN; TIMOLOL; UNINDEXED DRUG;

BIPOLAR DISORDER; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ECZEMA; ERYTHRODERMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LICHENOID; LUPUS ERYTHEMATOSUS; MALARIA; MENTAL DISEASE; NAIL DISEASE; NONHUMAN; OPEN ANGLE GLAUCOMA; PSORIASIS; PUSTULAR PSORIASIS; REVIEW; SIDE EFFECT; TACHYPHYLAXIS;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ANTIPSYCHOTIC AGENTS; HUMANS; LITHIUM; PSORIASIS; TETRACYCLINES;

EID: 78649400877     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04570.x     Document Type: Review

References (132)

1. Dika E, Varotti C, Bardazzi F, et al. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 2006; 25: 1-11.
2. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159-165.
3. Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007-1022.
4. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221-225.
5. Heng MCY, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Int J Dermatol 1988; 27: 619-627.
6. Knijff EM, Kupka RW, Ruwhof C. Evidence that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis. Bipolar Disorders 2005; 7: 388-389.
7. Yilmaz MB, Turhan H, Akin Y, et al. Beta-blocker-induced psoriasis: a rare side effect - a case report. Angiology 2002; 53: 737-739.
8. Halevy S, Feuerman EJ. Psoriasiform eruption induced by propranolol. Cutis 1979; 24: 95-98.
9. Gawkrodger DJ, Beveridge GW. Psoriasiform reaction to atenolol. Clin Exp Dermatol 1984; 9: 92-94.
10. White WB, Schulman P, McCabe EJ. Psoriasiform reaction to atenolol. Arch Dermatol 1986; 122: 857-858.
11. Sondergaard J, Wadskov S, Jensen HE, et al. Aggarvation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol (Stockh) 1976; 56: 239-243.
12. Gaylarde PM, Brocq AP, Sarkany I. Psoriasiform changes in guinea pig skin from propranolol. Clin Exp Dermatol 1978; 3: 157-160.
13. Wolf R, Shechter H, Brenner S. Induction of psoriasiform changes in guinea pig skin by propranolol. Int J Dermatol 1994; 33: 811-4.
14. Leonard JC. Oxprenolol and a psoriasis-like eruption. Lancet 1975; I: 630.
15. Cumberbatch JB. Skin reactions to beta-blockers. BMJ 1974; 4: 528.
16. Hudson WA, Finnis WA. Oxprenolol and a psoriasis-like eruption. Lancet 1975; 1: 932.
17. Berowa N, Tsankov N, Gruev A. Arzneimittelexantheme bei der Behandlung mit Beta-blockern. Dtsch Dermatologe 1984; 32: 1082-1089.
18. MacFarlane DG, Settas L. Acute psoriatic arthropathy precipitated by oxprenolol. Ann Rheum Dis 1984; 43: 102-104.
19. Assem ESK, Banks RA. Practolol induced drug eruptions. Proc R Soc Med 1973; 66: 179-181.
20. Cohran R, Thomson J, Fleming K, et al. The psoriasiform eruption induced by practolol: a clinicopathological study. J Cutan Pathol 1975; 2: 314-318.
21. Wright P. Untoward effects associated with practolol administration: oculo-mucocutaneous syndrome. BMJ 1975; 1: 595-598.
22. Kauppinen K, Niemi KM, Salo OP. Cutaneous reactions to practolol. Clinical and histopathological study. Ann Clin Res 1976; 8: 232-240.
23. Neumann HA, Van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor blocking agents. Dermatologica 1981; 162: 330-335.
24. Gawkrodger DJ, Beveridge GW. Psoriasiform reaction to atenolol. Clin Exp Dermatol 1984; 9: 92-94.
25. White WB, Schulman P, McCabe EJ. Psoriasiform cutaneous eruptions induced by cetamolol hydrochloride. Arch Dermatol 1986; 122: 857-858.
26. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19: 837-841.
27. Van Joost TH, Smitt HS. Skin reactions to propranolol and cross sensitivity to Β-adrenoreceptor blocking agents. Arch Dermatol 1981; 117: 600-601.
28. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998; 16: 333-351.
29. Puig L, Goni FJ, Roque AM, et al. Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol 1989; 108: 455-456.
30. Coignet M, Sayag J. Collyre beta-bloquant et psoriasis. Nouv Dermatol 1990; 9: 552-553.
31. Puig L, Goni FJ, Roque AM, et al. Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol 1989; 108: 455-456.
32. Tsankov N, Pramatarov K, Kamarachev J. Psoriasis pla-cata, die unter der Einwirkung der Beta-Blocker in eine Psoriasis pustulosa ubergeht. Dtsch Dermatologe 1992; 40: 1702-1706.
33. Cohen AD, Bonneh DY, Reuveni M, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta DermVenereol 2005; 85: 299-303.
34. O' Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006; 5: 426-432.
35. Assem ESK, Banks RA. Practolol induced drug eruptions. Proc R Soc Med 1973; 66: 179-181.
36. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol - the role of an immunological mechanism. Arch Dermatol Res 1991; 283: 472-473.
37. Raftery EB, Denman AM. Systemic lupus erythematosus syndrome induced by practolol. BMJ 1973; 2: 452-455.
38. Voorkhees JJ, Duell EA. Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade; a defective chalone mechanism? Arch Dermatol 1982; 118: 862-868.
39. Voorhees JJ, Duell EA. Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade; a defective chalone mechanism? Arch Dermatol 1971; 104: 352-358.
40. Steinkraus V, Mensing H. Psoriasis under beta-blockade. Hautarzt 1992; 43: 179-183.
41. Ockenfels HM, Nussbaum G, Schultewolter T, et al. Tyrosine phosphorylation in psoriasis T cells is modified by drugs that induce or improve psoriasis. Dermatology 1995; 191: 217-225.
42. Carter TN. The relationship of lithium carbonate psoriasis. Psychosomatics 1972; 13: 325-327.
43. Bakker JB, Pepplinkhuizen L. More about the relationship of lithium to psoriasis. Psychosomatics 1976; 17: 143-146.
44. Heng MCY. Cutaneous manifestation of lithium toxicity. Br J Dermatol 1982; 106: 107-109.
45. Sasaki T, Saito S, Aihara M, et al. Exacerbation of psoriasis during lithium treatment. J Dermatol 1989; 16: 59-63.
46. Skott A, Mobacken H, Starmark JE. Exacerbation of psoriasis during lithium therapy. Br J Dermatol 1977; 96: 445-448.
47. Hanada K, Tasaki M, Hashimoto I, et al. Development of psoriasis-like syndrome following lithium therapy. Biol Trace El Res 1978; 14: 169-177.
48. White SW. Palmoplanter pustular psoriasis provoked by lithium therapy. J Am Acad Dermatol 1982; 7: 660-662.
49. Lowe NJ, Ridgway HB. Generalized pustular psoriasis precipitated by lithium carbonate. Arch Dermatol 1971; 104: 352-358.
50. Skoven J, Thormann J. Lithium compound treatment and psoriasis. Arch Dermatol 1979; 115: 1185-1187.
51. Yeung CK, Chan HHL. Cutaneous side effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3-8.
52. Paduart O, Heenen M. Pharmacological action of lithium in the pathogenesis of psoriasis. Eur J Dermatol 1995; 5: 425-443. 413-415.
53. Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium 1992; 26: 211-212.
54. Di Giovanna JJ, Aoyagai T, Taylor RT, et al. Inhibition of epidermal adenyl cyclase by lithium carbonate. J Invest Dermatol 1981; 76: 259-263.
55. Beyaert R, Schulze-Osthoff K, Van Roy F. Synergic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. Eur J Immunol 1992; 22: 2181-2184.
56. Ockenfels HM, Wagner SN, Klim-Maas C, et al. Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res 1996; 288: 173-178.
57. Voorhees JJ, Marcelo CL, Duell EA. Cyclic AMP, cyclic GMP and glucocorticoids as potential metabolic regulators of epidermal proliferation and differentiation. J Invest Dermatol 1975; 65: 179-190.
58. Bloomfield FJ, Young MM. Enhanced release of inflammatory mediators from lithium-stimulated neutrophils in psoriasis. Br J Dermatol 1983; 109: 9-13.
59. Grisaru N, Belmaker RH. Lithium dosage and inositol levels. Br J Psychiatry 1994; 164: 133-134.
60. Allan SJ, Kavanagh GM, Herd RM, et al. The effect of inosiotol supplements on the psoriasis of the patients taking lithium: a randomized placeo-controlled trial. Br J Dermatol 2004; 150: 966-969.
61. Kniff EM, Kupka RW, Ruwhof C, et al. Evidence that immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis. Bipolar Disord 2005; 7: 388-389.
62. Wolf R, D'Avino M, De Angelis F, et al. Effects of lithium of lithium carbonate (Lico3) on in-vitro cultured normal skin explants. J Eur Acad Dermatol Venereol 2000; 14: 97-99.
63. Lin X-R, Huang T, Yang CM. Histological changes induced by application of lithium carbonate to mouse ear skin. Arch Dermatol Res 1990; 282: 280-281.
64. Namazi MR. Aggravation of psoriasis by antimalarials: a comment on the pathogenic mechanism. Indian J Dermatol Venereol Leprol. 2008; 74: 675-676.
65. Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol 1992; 119: 269-274.
66. Tanenbaum L, Tuffanelli DL. Antimalarial agents: chloroquine, hydroxychloroquine and quinacrine. Arch Dermatol 1980; 116: 587-591.
67. Friedman SS. Pustular psoriasis associated with hydroxychloroquine. J Am Acad Dermatol 1987; 16: 1256-1257.
68. Cornbleet T. Preliminary and short report: action of synthetic antimalarial drugs on psoriasis. J Invest Dermatol 1956; 22: 435-436.
69. Slagel GA, James WD. Plaquenil induced erythroderma. J Am Acad Dermatol 1985; 12: 857-862.
70. Baker H. The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagicum. Br J Dermatol 1966; 78: 161-166.
71. Bielicky T, Kvicalova E. Photosensitive psoriasis. Dermatologica 1964; 129: 339-348.
72. Trnavsky K, Zbojanova M, Vloek F. Antimalarials in psoriatic arthritis. J Rheumatol 1983; 10: 833-834.
73. Kammer GM, Sotar NA, Gibson DJ. Psoriatic arthritis: a clinical, immunologic, and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9: 75-95.
74. Tsankov N, Stoimenov A, Lazarova A. Psoriasis induit par la chloroquine chez un malade ayant un lupus erythemateux discoide. Rev Eur Dermatol MST 1990; 2: 453-458.
75. Wolf R, Schiavo AL. Is transglutaminase the mediator between antimalarial drugs and psoriasis? Int J Dermatol 1997; 36: 10-13.
76. Ellis CN, Fallon JD, Heezen JL, Voorhees JJ. Topical indomethacin exacerbates lesions of psoriasis. J Invest Dermatol 1983; 80: 362.
77. Powles AV, Griffiths CEM, Seifert MH, et al. Exacerbation of psoriasis by indomethacin. Br J Dermatol 1987; 117: 799-800.
78. Lazarova AZ, Tsankov NK, Zlatkov NB. Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol 1989; 14: 2601.
79. Ellis CN, Fallon JD, Heezen JL, et al. Topical indomethacin exacerbates lesions of psoriasis. J Invest Dermatol 1983; 80: 362.
80. Katayama H, Kawada A. Exacerbation of psoriasis induced by indomethacin. J Dermatol (Tokyo) 1981; 8: 323-327.
81. Lazarova AZ, Tsankov NK, Zlatkov NB. Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol 1989; 14: 2601.
82. Reshod H, Hargreaves GK, Vickers CF. Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenylbutazone. Br J Dermatol 1983; 109: 111-113.
83. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Ebling EJG, eds. Textbook of Dermatology, Vol 2. Oxford: Blackwell Scientific Publications, 1992: 1391-1457.
84. Lammers AM, Van de Kerkof PCM. Leucotriene B4 fails to induce penetration of polymorphonuclear leucocytes into psoriatic lesions. Br J Dermatol 1987; 117: 541-544.
85. Katz M. Penicillin-induced generalised pustular psoriasis. J Am Acad Dermatol 1987; 17: 918-920.
86. Whittan LR, Wakelin SH, Barker JN. Generalised pustular psoriasis or drug induced pustulo derma. The use of patch testing. Clin Exp Dermatol 2000; 25: 122-124.
87. Epelbaum S. Acute generalised exanthematous pustulosis. Pediatric 1989; 44: 387-389.
88. Tsankov N, Krasteva M. Rifampin therapy in severe forms of psoriasis. J Dermatol Treat 1992; 3: 69-71.
89. Tsankov N, Kamarashev J. Rifampin in dermatology. Int J Dermatol 1993; 32: 401-406.
90. Flandin F. L'action de la pénicilline dans le psoriasis. Bull Soc Fr Dermatol Syphiligr 1959; 66: 494-500.
91. Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. J Am Acad Dermatol 1986; 14: 761-764.
92. Botev-Zlatkov N, Tsankov N, Tonev S, et al. Drug therapy deteriorates the course of psoriasis. 17th World Congress of Dermatology, Part II, West Berlin, 1987: 216.
93. Cohen-Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris with reference to their role in the pathogenesis of this disease. Dermatologica 1970; 140: 289-290.
94. Tsankov N, Vassileva S, Lazarova A, et al. Onset of psoriasis coincident with tetracycline therapy. Aust J Dermatol 1988; 29: 111-112.
95. Tsankov N, Botev-Zlatkov N, Lazarova A, et al. Psoriasis and drugs: influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol 1988; 19: 629-632.
96. Tsankov N, Lazarova A. Psoriasis and tetracyclines [reply]. J Am Acad Dermatol 1990; 23: 770-771.
97. Tsankov N, Lazarova A, Nikolova A. Psoriasis vulgarte et tétracyclines. A propos de deux cas. Nouv Dermatol 1995; 14: 393-395.
98. Tsankov N, Gantcheva M, Pecheva M, et al. Doxycicline induced psoriasis vulgaris. Dermatol i Venerol (Sofia) 1994; 33: 31-32.
99. Counis R, Koumanov K, Ranlin J, et al. Antilipolytic role of tetracycline. Inhibition of adenylate cyclase in vitro. Eur J Biochem 1973; 37: 244-247.
100. 2 activity is raised in uninvolved epidermis of psoriasis. Br J Dermatol 1983; 108: 103-105.
101. Boothe JH. The tetracyclines. In: Hlavka JJ, ed. Handbook of Experimental Pharmacology, Vol 78. The Tetracyclines. Berlin: Springer-Verlag, 1985.
102. Wright AL, Colver GB. Tetracyclines - how safe are they? Clin Exp Dermatol 1988; 13: 57-61.
103. Powles AV, Baker BS, Rutman AJ, et al. Epidermal rupture is the initiating factor for the Koebner response in psoriasis. Acta Derm Venereol 1990; 70: 35-38.
104. David M, Livni E, Stern E, et al. Psoriasiform eruption induced by digoxin. Confirmed by re-exposure. J Am Acad Dermatol 1981; 5: 702-703.
105. Wilkin J. Exacerbation of psoriasis during clonidine therapy. Arch Dermatol 1981; 117: 4.
106. Muir AD. Amioderone and psoriasis. N Z Med J 1982; 95: 711.
107. Harwell WB. Quinidine induced psoriasis. J Am Acad Dermatol 1983; 9: 278.
108. Hemlock CF, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992; 26: 211-212.
109. Brenner S, Wolf R, Landau M, et al. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci 1994; 30: 283-286.
110. Latini A, Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol 2003; 13: 404-405.
111. Baker HS, Ryan TJ. Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80: 771-793.
112. Roberts DL. Irritancy of anthralin in patients with psoriasis and widespread vitiligo. Br J Dermatol 1984; 110: 247-248.
113. Gocalo S, Sousa I, Moreno A. Contact dermatitis to coal tar. Contact Dermatitis 1984; 10: 57-58.
114. Ogawa M, Baughman RD, Clendenning WE. Generalized pustular psoriasis: induction by topical use of coal tar. Arch Dermatol 1969; 99: 671-673.
115. Funk J. Psoriasis induced by alpha-interferon. Br J Dematol 1991; 1254: 463-465.
116. Navne JE, Hedegaard U, Bygum A. Activation of psoriasis in patients undergoing treatment with Β-interferon. Ugeskr Laeger 2005; 167: 2903-2904.
117. Fanti PA, Dika E, Vaccari S, et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-1465.
118. Andersen M. Exacerbation of psoriasis during treatment with H2 antagonists. Ugeskr Laeger 1991; 153: 132.
119. Fisher DA, Elia PM, Leboit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol 1988; 124: 854-855.
120. Garcia-Lora E, Tercedor J, Massare E, et al. Interferon induced psoriasis in a patient with chronic hepatitis C. Dermatology 1995; 190: 173.
121. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990; 126: 351-355.
122. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-150.
123. Hartmann F, Von Wussow P, Deicher H. Exacerbation of psoriasis during alpha-interferon therapy. Dtsch Med Wochenschr 1989; 114: 96-98.
124. Kartal ED, Colak H, Ozgunes I, et al. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005; 51: 167-169.
125. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88: 1756-1758.
126. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; 1: 1466-1468.
127. Borrás-Blasco J, Gracia-Perez A, Nuñez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008; 33: 321-325.
128. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.
129. Wendling D, Balblanc JC, Briançon D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008; 75: 315-318.
130. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-2729.
131. Cuchacovich R, Espinoza CG, Virk Z, et al. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol 2008; 14: 353-356.
132. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006; 65: 405-407.